Agenus Company Profile (NASDAQ:AGEN)

About Agenus

Agenus logoAgenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP)-based vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AGEN
  • CUSIP: 00847G70
Key Metrics:
  • Previous Close: $3.85
  • 50 Day Moving Average: $4.024
  • 200 Day Moving Average: $5.134
  • 52-Week Range: $2.73 - $7.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.05
  • P/E Growth: 0.000
  • Market Cap: $335.00M
  • Outstanding Shares: 87,126,000
  • Beta: 2.51
Profitability:
  • Net Margins: -472.80%
  • Return on Equity: -359.98%
  • Return on Assets: -47.88%
Debt:
  • Debt-to-Equity Ratio: -6.00%
  • Current Ratio: 3.14%
  • Quick Ratio: 3.14%
Additional Links:
Companies Related to Agenus:

Analyst Ratings

Consensus Ratings for Agenus (NASDAQ:AGEN) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $9.80 (154.88% upside)

Analysts' Ratings History for Agenus (NASDAQ:AGEN)
Show:
DateFirmActionRatingPrice TargetDetails
2/16/2017HC WainwrightSet Price TargetHold$5.00View Rating Details
12/1/2016JMP SecuritiesReiterated RatingBuyView Rating Details
10/27/2016Maxim GroupReiterated RatingBuy$7.00View Rating Details
8/23/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$17.00 -> $15.00View Rating Details
12/31/2015Oppenheimer Holdings, Inc.Reiterated RatingPositive -> Outperform$14.00View Rating Details
9/10/2015William BlairReiterated RatingBuyView Rating Details
7/27/2015MLV & Co.Reiterated RatingBuy$9.00 -> $11.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Agenus (NASDAQ:AGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017        
10/27/2016Q316($0.29)($0.47)$6.15 million$4.45 millionViewListenView Earnings Details
7/28/2016Q216($0.34)($0.33)$5.12 million$6.59 millionViewListenView Earnings Details
4/28/2016Q116($0.23)($0.37)$5.16 millionViewListenView Earnings Details
3/3/2016Q415($0.17)($0.18)$9.39 million$7.64 millionViewListenView Earnings Details
10/27/2015Q315($0.15)($0.16)$7.56 millionViewListenView Earnings Details
7/23/2015Q215($0.15)($0.44)$5.71 million$6.38 millionViewListenView Earnings Details
4/23/2015Q115($0.01)($0.28)$11.66 million$3.95 millionViewN/AView Earnings Details
2/26/2015Q414($0.16)($0.41)$1.62 millionViewN/AView Earnings Details
10/31/2014Q314($0.15)($0.13)$1.96 million$1.56 millionViewN/AView Earnings Details
7/24/2014Q214($0.17)($0.12)$3.07 millionViewN/AView Earnings Details
5/8/2014Q114($0.13)($0.01)$0.55 million$0.72 millionViewN/AView Earnings Details
3/5/2014Q413($0.24)($0.16)$870.00 million$393.00 millionViewN/AView Earnings Details
10/24/2013Q313($0.27)($0.24)$736.00 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.21)($0.40)ViewN/AView Earnings Details
2/28/2013Q4 2012($0.24)($0.23)$0.72 million$1.09 millionViewN/AView Earnings Details
7/28/2011($0.05)($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Agenus (NASDAQ:AGEN)
Current Year EPS Consensus Estimate: $-1.450 EPS
Next Year EPS Consensus Estimate: $-1.260 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.18)($0.18)($0.18)
Q2 20161($0.39)($0.39)($0.39)
Q3 20162($0.44)($0.33)($0.39)
Q4 20162($0.47)($0.35)($0.41)
Q1 20171($0.24)($0.24)($0.24)
Q2 20171($0.24)($0.24)($0.24)
Q3 20171($0.25)($0.25)($0.25)
Q4 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Agenus (NASDAQ:AGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Agenus (NASDAQ:AGEN)
Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 45.40%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/14/2017Corp IncyteMajor ShareholderBuy10,000,000$6.00$60,000,000.00View SEC Filing  
9/6/2016Ulf WiinbergDirectorBuy30,000$6.29$188,700.00View SEC Filing  
5/9/2016Garo H ArmenCEOBuy100,000$3.18$318,000.00View SEC Filing  
5/5/2016Ozer BaysalInsiderBuy2,250$3.10$6,975.00View SEC Filing  
3/7/2016Garo H ArmenCEOBuy200,000$4.03$806,000.00View SEC Filing  
12/29/2015Garo H. ArmenCEOSell219,576$4.59$1,007,853.84View SEC Filing  
12/28/2015Garo H. ArmenCEOSell134,352$4.60$618,019.20View SEC Filing  
9/25/2015Charles Evan BallantyneCFOBuy10,000$5.05$50,500.00View SEC Filing  
9/25/2015Garo H ArmenCEOBuy100,000$5.03$503,000.00View SEC Filing  
4/29/2015Shahzad MalikDirectorSell1,107,377$7.11$7,873,450.47View SEC Filing  
1/9/2015Qvt Associates Gp LlcMajor ShareholderSell2,343,630$5.31$12,444,675.30View SEC Filing  
1/23/2014Karen ValentineVPSell2,850$3.50$9,975.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Agenus (NASDAQ:AGEN)
DateHeadline
News IconChiefs sign running back CJ Spiller (NASDAQ:AGEN)
ekosvoice.com - February 24 at 8:24 PM
News IconMore Support for Those Helping Refugee Asylum Seekers in Manitoba (NASDAQ:AGEN)
latribunadecanarias.com - February 24 at 8:24 PM
News IconAgenus Inc. (AGEN) Reviewed By Analysts (NASDAQ:AGEN)
nyhetsbanken.info - February 24 at 8:24 PM
News IconAgenus Inc. (NASDAQ:AGEN), Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) (NASDAQ:AGEN)
hoyentv.com - February 24 at 8:24 PM
marketexclusive.com logoTrials Of Agenus Inc (NASDAQ:AGEN) Cancer Vaccine Ends In Absolute Failure (NASDAQ:AGEN)
marketexclusive.com - February 24 at 10:38 AM
4-traders.com logoAgenus : Chairman's Update (NASDAQ:AGEN)
www.4-traders.com - February 24 at 10:38 AM
News IconLooking at the Levels on Shares of Agenus Inc. (NASDAQ:AGEN) - BVN (NASDAQ:AGEN)
bvnewsjournal.com - February 23 at 3:24 PM
News IconForward Earnings Estimate of Agenus Inc.(AGEN) - Highland Mirror (NASDAQ:AGEN)
www.highlandmirror.com - February 23 at 3:24 PM
fool.com logoTroubling Trial Data Weighed on Agenus Inc Stock Today - Motley Fool (NASDAQ:AGEN)
www.fool.com - February 22 at 8:27 PM
fool.com logoTroubling Trial Data Weighed on Agenus Inc Stock Today (NASDAQ:AGEN)
www.fool.com - February 22 at 8:26 PM
News IconAgenus Inc. NASDAQ:AGEN Placed on Most Volatile List - Aiken Advocate (NASDAQ:AGEN)
aikenadvocate.com - February 22 at 3:25 PM
marketexclusive.com logoAGENUS INC. (NASDAQ:AGEN) Files An 8-K Regulation FD ... - Market Exclusive (NASDAQ:AGEN)
marketexclusive.com - February 22 at 3:25 PM
biz.yahoo.com logoAGENUS INC Files SEC form 8-K, Regulation FD Disclosure (NASDAQ:AGEN)
biz.yahoo.com - February 22 at 11:40 AM
bizjournals.com logoLexington's Agenus quietly discloses failure of cancer vaccine trial (NASDAQ:AGEN)
www.bizjournals.com - February 22 at 11:40 AM
seekingalpha.com logoAgenus shuts down mid-stage study of Prophage G-200 due to lack of treatment effect; shares ease 5% premarket (NASDAQ:AGEN)
seekingalpha.com - February 22 at 8:42 AM
News IconBuy, Sell or Hold? Analysts Approach: Agenus Inc. (AGEN), Varian Medical Systems, Inc. (VAR)? - The USA Commerce (NASDAQ:AGEN)
theusacommerce.com - February 21 at 3:39 PM
News IconConsensus Buys According to Analysts: Agenus Inc. (NASDAQ:AGEN) Evolution Petroleum Corporation (ASX:EPM) - Rives Journal (NASDAQ:AGEN)
rivesjournal.com - February 18 at 3:21 PM
marketexclusive.com logoAGENUS INC. (NASDAQ:AGEN) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:AGEN)
marketexclusive.com - February 16 at 8:27 PM
marketexclusive.com logoAGENUS INC. (NASDAQ:AGEN) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:AGEN)
marketexclusive.com - February 16 at 8:27 PM
us.rd.yahoo.com logoIncyte and Agenus Amend Collaboration Agreement (NASDAQ:AGEN)
us.rd.yahoo.com - February 16 at 8:27 PM
us.rd.yahoo.com logoIncyte and Agenus Amend Collaboration Agreement (NASDAQ:AGEN)
us.rd.yahoo.com - February 16 at 8:27 PM
biz.yahoo.com logoAGENUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Fi (NASDAQ:AGEN)
us.rd.yahoo.com - February 16 at 8:27 PM
biz.yahoo.com logoAGENUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Fi (NASDAQ:AGEN)
us.rd.yahoo.com - February 16 at 8:27 PM
News IconMarket Update on Shares of Agenus Inc. (AGEN) - BVN (NASDAQ:AGEN)
bvnewsjournal.com - February 16 at 3:26 PM
istreetwire.com logoAgenus Inc. (AGEN), Fitbit, Inc. (FIT), Coeur Mining, Inc. - iStreetWire - iStreetWire (NASDAQ:AGEN)
istreetwire.com - February 16 at 7:12 AM
News IconChecking in on Signals for Agenus Inc. (AGEN) - BVN (NASDAQ:AGEN)
bvnewsjournal.com - February 14 at 3:39 PM
News IconAgenus Inc. (NASDAQ:AGEN) Bending Lower, Touching Top Loser's List - Aiken Advocate (NASDAQ:AGEN)
aikenadvocate.com - February 14 at 3:39 PM
streetinsider.com logoAGENUS INC. - StreetInsider.com (NASDAQ:AGEN)
www.streetinsider.com - February 14 at 3:39 PM
investopedia.com logoIncyte and Agenus Amend Drug Licensing Deal (NASDAQ:AGEN)
www.investopedia.com - February 14 at 3:39 PM
bizjournals.com logo​Lexington-based Agenus reworks Incyte pact, freeing up $80M in cash (NASDAQ:AGEN)
www.bizjournals.com - February 14 at 3:39 PM
fool.com logoWhy Agenus Stock Is Surging Today (NASDAQ:AGEN)
www.fool.com - February 14 at 12:15 PM
News IconWhere is Agenus Inc. (NASDAQ:AGEN) Headed Near Term? - Rockville Register (NASDAQ:AGEN)
rockvilleregister.com - February 14 at 1:22 AM
News IconTrading Watch for Agenus Inc. (NASDAQ:AGEN) - Benton Bulletin (NASDAQ:AGEN)
bentonbulletin.com - February 10 at 8:52 PM
reuters.com logoBRIEF-Venbio Select Advisor LLC reports a 5.41 pct passive stake in Agenus (NASDAQ:AGEN)
www.reuters.com - February 9 at 8:25 PM
capitalcube.com logoAgenus, Inc. – Value Analysis (NASDAQ:AGEN) : February 8, 2017 (NASDAQ:AGEN)
www.capitalcube.com - February 8 at 3:27 PM
fool.com logo3 Growth Stocks That Could Double (NASDAQ:AGEN)
www.fool.com - February 8 at 10:05 AM
News IconAgenus Inc AGEN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:AGEN)
www.bioportfolio.com - February 8 at 1:44 AM
capitalcube.com logoAgenus, Inc. breached its 50 day moving average in a Bullish Manner : AGEN-US : February 7, 2017 (NASDAQ:AGEN)
us.rd.yahoo.com - February 8 at 1:44 AM
fool.com logoBetter Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc. -- The ... - Motley Fool (NASDAQ:AGEN)
www.fool.com - February 6 at 3:25 PM
investornewswire.com logoAgenus Inc. (NASDAQ:AGEN) Records An Impact Score Of 40 - Investor Newswire (NASDAQ:AGEN)
www.investornewswire.com - February 4 at 3:27 PM
reuters.com logoBRIEF-QVT Financial reports 5.08 pct passive stake in Agenus (NASDAQ:AGEN)
in.reuters.com - February 3 at 8:20 PM
News IconStocks Faring Away From Broker's Choice: Valeant Pharmaceuticals International (NYSE:VRX), Agenus (NASDAQ:AGEN)
prensariotiretail.com - February 2 at 1:54 AM
News IconFree Cash Flow Score in Focus for Agenus Inc. (NASDAQ:AGEN) - The Tribune (NASDAQ:AGEN)
lakecitytribune.com - February 1 at 3:16 PM
prnewswire.com logoAgenus Appoints Jean-Marie Cuillerot, M.D. Chief Medical Officer - PR Newswire (press release) (NASDAQ:AGEN)
www.prnewswire.com - January 31 at 1:07 AM
streetinsider.com logoAgenus (AGEN) Names Jean-Marie Cuillerot to CMO (NASDAQ:AGEN)
www.streetinsider.com - January 30 at 8:05 PM
News IconChecking the Levels on Shares of Agenus Inc. (NASDAQ:AGEN) - The Tribune (NASDAQ:AGEN)
lakecitytribune.com - January 30 at 3:03 PM
finance.yahoo.com logo9:00 am Agenus appoints Jean-Marie Cuillerot, M.D. as Chief Medical Officer (NASDAQ:AGEN)
finance.yahoo.com - January 30 at 3:03 PM
finance.yahoo.com logoAgenus Appoints Jean-Marie Cuillerot, M.D. Chief Medical Officer (NASDAQ:AGEN)
finance.yahoo.com - January 30 at 3:03 PM
News IconVolatility Watch on Shares of Agenus Inc. (NASDAQ:AGEN) - Gilbert Daily (NASDAQ:AGEN)
gilbertdaily.com - January 30 at 1:24 AM
News IconThis Weeks Target Prices For Agenus Inc. (AGEN) - NewsDen (NASDAQ:AGEN)
newsden.net - January 28 at 3:24 PM

Social

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Where is Agenus' stock going? Where will Agenus' stock price be in 2017?

5 analysts have issued twelve-month price targets for Agenus' shares. Their predictions range from $5.00 to $15.00. On average, they anticipate Agenus' share price to reach $9.80 in the next year.

When will Agenus announce their earnings?

Agenus is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

What are analysts saying about Agenus stock?

Here are some recent quotes from research analysts about Agenus stock:

  • According to Zacks Investment Research, "Agenus focuses on the development of checkpoint modulators, vaccines and adjuvants for cancer treatments. With no approved product in its portfolio, the company is heavily dependent on its collaborators for top-line growth. In addition, the company is dependent on its partners for pipeline development. Moreover, Agenus has few candidates in mid-stage of development including Prophage vaccine and several QS-21 Stimulon-containing vaccine candidates. Any unfavorable outcome from the studies may affect the company’s shares adversely. However, the company received a boost when Merck selected its lead antibody candidate and several backup antibodies for an undisclosed checkpoint target. Moreover, the company’s collaboration agreements provide a steady source of funds. Agenus’ shares have outperformed the Medical/Biomedical Genetics industry." (12/27/2016)

  • Maxim Group analysts commented, "Agenus reported 2Q16 with $6.6M in revenue and a net loss of $60.2M or ($0.33)." (7/28/2016)

Who owns Agenus stock?

Agenus' stock is owned by many different of institutional and retail investors. Top institutional investors include RTW Investments LP (4.83%), State Street Corp (4.02%), FMR LLC (1.86%), Marshall Wace LLP (0.57%), Allianz Asset Management AG (0.28%) and Bruce & Co. Inc. (0.18%). Company insiders that own Agenus stock include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal, Shahzad Malik and Ulf Wiinberg.

Who sold Agenus stock? Who is selling Agenus stock?

Agenus' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Allianz Asset Management AG and Metropolitan Life Insurance Co. NY.

Who bought Agenus stock? Who is buying Agenus stock?

Agenus' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Marshall Wace LLP, Glenview Trust Co, Perceptive Advisors LLC, RTW Investments LP, AQR Capital Management LLC, A.R.T. Advisors LLC and First Allied Advisory Services Inc.. Company insiders that have bought Agenus stock in the last two years include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg.

How do I buy Agenus stock?

Shares of Agenus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Agenus stock cost?

One share of Agenus stock can currently be purchased for approximately $3.85.

Agenus (NASDAQ:AGEN) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Earnings History Chart

Earnings by Quarter for Agenus (NASDAQ:AGEN)

Dividend History Chart

Dividend Payments by Quarter for Agenus (NASDAQ:AGEN)

Last Updated on 2/25/2017 by MarketBeat.com Staff